NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.

Overview

abstract

These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Guérin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice.

authors

Spiess, Philippe E

Agarwal, Neeraj

Boorjian, Stephen A

Buyyounouski, Mark K

Efstathiou, Jason A

Flaig, Thomas W

Friedlander, Terence

Greenberg, Richard E

Guru, Khurshid A

Herr, Harry Wallace
Hoimes, Christopher
Inman, Brant A
Kader, A Karim
Kibel, Adam S
Kuzel, Timothy M
Lele, Subodh M
Meeks, Joshua J
Michalski, Jeff
Montgomery, Jeffrey S
Pagliaro, Lance C
Pal, Sumanta K
Patterson, Anthony
Petrylak, Daniel
Plimack, Elizabeth R
Pohar, Kamal S
Porter, Michael P
Sexton, Wade J
Siefker-Radtke, Arlene O
Sonpavde, Guru
Tward, Jonathan
Wile, Geoffrey
Dwyer, Mary A
Smith, Courtney

publication date

October 1, 2016

published in

Journal of the National Comprehensive Cancer Network : JNCCN Journal

Research

keywords

Antineoplastic Agents
Urinary Bladder Neoplasms

Identity

PubMed Central ID

PMC5379654

Scopus Document Identifier

84990174465

Digital Object Identifier (DOI)

10.6004/jnccn.2016.0131

PubMed ID

27697976

Additional Document Info

has global citation frequency

79

volume

14

issue

10